Neue Therapieoptionen bei Migräne: CGRP-blockierende Substanzen im Blickpunkt

Translated title of the contribution: New treatment options for migraine: Focus on CGRP blocking substances

K. Meßlinger, M. Dux

Research output: Contribution to journalArticle

Abstract

Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are largely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) or inhibiting CGRP receptors by non-peptide antagonists (gepants). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to liver toxic effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition within and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

Original languageGerman
Pages (from-to)492-500
Number of pages9
JournalNervenheilkunde
Volume35
Issue number7-8
Publication statusPublished - 2016

Fingerprint

Calcitonin Gene-Related Peptide
Migraine Disorders
Calcitonin Gene-Related Peptide Receptors
Tryptamines
Secondary Headache Disorders
Serotonin 5-HT1 Receptor Agonists
Therapeutics
Antibodies, Monoclonal, Humanized
Poisons
Neuropeptides
Clinical Trials
Safety
Drug Therapy
Pain
Liver

Keywords

  • Calcitonin gene-related peptide
  • CGRP antagonists
  • Chronic migraine
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Clinical Neurology
  • Family Practice

Cite this

Neue Therapieoptionen bei Migräne : CGRP-blockierende Substanzen im Blickpunkt. / Meßlinger, K.; Dux, M.

In: Nervenheilkunde, Vol. 35, No. 7-8, 2016, p. 492-500.

Research output: Contribution to journalArticle

@article{3b5372089f694823ba579210d3fabf8a,
title = "Neue Therapieoptionen bei Migr{\"a}ne: CGRP-blockierende Substanzen im Blickpunkt",
abstract = "Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are largely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) or inhibiting CGRP receptors by non-peptide antagonists (gepants). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to liver toxic effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition within and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.",
keywords = "Calcitonin gene-related peptide, CGRP antagonists, Chronic migraine, Monoclonal antibodies",
author = "K. Me{\ss}linger and M. Dux",
year = "2016",
language = "German",
volume = "35",
pages = "492--500",
journal = "Nervenheilkunde",
issn = "0722-1541",
publisher = "Schattauer GmbH",
number = "7-8",

}

TY - JOUR

T1 - Neue Therapieoptionen bei Migräne

T2 - CGRP-blockierende Substanzen im Blickpunkt

AU - Meßlinger, K.

AU - Dux, M.

PY - 2016

Y1 - 2016

N2 - Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are largely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) or inhibiting CGRP receptors by non-peptide antagonists (gepants). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to liver toxic effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition within and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

AB - Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are largely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) or inhibiting CGRP receptors by non-peptide antagonists (gepants). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to liver toxic effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition within and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

KW - Calcitonin gene-related peptide

KW - CGRP antagonists

KW - Chronic migraine

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84979792043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979792043&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84979792043

VL - 35

SP - 492

EP - 500

JO - Nervenheilkunde

JF - Nervenheilkunde

SN - 0722-1541

IS - 7-8

ER -